Kura Oncology, Inc.

KURA Nasdaq SEC CIK 1422143
Follow Kura Oncology Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $22.8M +10.1% vs same quarter last year
Net income −$70.2M +5.3% vs same quarter last year
EPS, diluted −$0.78 +8.2% vs same quarter last year
Operating cash flow −$54.4M +32.5% vs same quarter last year
Revenue by quarter
$14.1M
$15.3M
$20.8M
$17.3M
$18.3M
$20.9M
$22.8M
Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income15 fiscal years
  • Revenue
  • Net income
−$300M−$200M−$100M$0$100MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$67.5M−$278.7M
FY24$53.9M−$174M
FY23$0−$152.6M
FY22-−$135.8M
FY21-−$130.5M
FY20-−$89.6M
FY19-−$63.1M
FY18-−$60.4M
FY17-−$35.4M
FY16-−$27.6M
FY15-−$22.6M
FY14-−$30.7K
FY13-−$28.6K
FY12-−$27.3K
FY11-−$27K
Free cash flowOperating cash flow minus capital expenditure
−$200M−$100M$0$100M$200MFY11FY13FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25−$70.7M
FY24$133.8M
FY23−$125M
FY22−$110.7M
FY21−$105.7M
FY20−$72M
FY19-
FY18-
FY17-
FY16-
FY15−$18M
FY14-
FY13-
FY12-
FY11-